Pancreatic Cancer
Seprase (FAP) is a serine protease highly expressed in pancreatic cancer-associated fibroblasts (CAFs) and tumor stroma. It promotes tumor invasion, metastasis, and immunosuppression, making it a promising therapeutic target. Alfa Cytology offers comprehensive preclinical services for seprase (FAP)-targeted diagnostics and therapeutics development, specifically tailored for pancreatic cancer. From molecular imaging to multi-platform drug development, we accelerate your pipeline with precision.
Introduction to Pancreatic Cancer
Seprase (FAP) is overexpressed in >90% of pancreatic ductal adenocarcinoma (PDAC) cases, particularly in the tumor microenvironment (TME). It drives extracellular matrix (ECM) remodeling, immune evasion, and chemoresistance, correlating with poor prognosis. Targeting seprase (FAP) disrupts CAF-tumor crosstalk, offering a novel strategy to combat PDAC progression.
Fig. 1 CAFs in PDAC originate from diverse cells. (Zhang, T., et al. 2022)
Seprase (FAP)-Targeted Drug Development for Pancreatic Cancer
| Name | Indication | Company | Phase |
| FAP-Targeted CAR-T | Advanced PDAC | Fate Therapeutics | Preclinical |
| FAP-2286 (FAPi-based RLT) | Metastatic PDAC | Novartis/3BP | Phase I/II |
Disclaimer: Alfa Cytology focuses on providing preclinical research service. This table is for information exchange purposes only. This table is not a treatment plan recommendation. For guidance on treatment options, please visit a regular hospital.
Our Services
At Alfa Cytology, our team of experts brings extensive experience and knowledge, utilizing cutting-edge technologies to drive innovation. We are committed to delivering high-quality services that meet the specific needs of our clients, from target validation to preclinical studies. With a focus on seprase (FAP)-targeted therapy, we aim to provide effective drug development solutions for pancreatic cancer.
One-Stop Solutions
Our Pancreatic Cancer Modeling Services
Alfa Cytology establishes cell culture-based methods for tumor cell isolation and expansion for further molecular and functional testing, including in vitro 2D culture systems.
Alfa Cytology understands the different types of cell culture conditions that can support normal and malignant human pancreatic tissue culture.
To investigate and evaluate novel therapies, Alfa Cytology has launched a systematic pancreatic cancer research animal model platform.
If you are interested in our seprase (FAP)-targeted therapeutic drug development services for pancreatic cancer or have any questions, please do not hesitate to contact Alfa Cytology. We are eager to collaborate with you and explore the potential of seprase (FAP)-targeted therapy in pancreatic cancer treatment.
Reference
- Zhang, T., et al. Cancer-associated fibroblasts in pancreatic ductal adenocarcinoma. Cell death & disease. 2022, 13(10): 897.
For research use only.